000300094 001__ 300094
000300094 005__ 20250411112850.0
000300094 0247_ $$2doi$$a10.1016/j.modpat.2025.100757
000300094 0247_ $$2pmid$$apmid:40118460
000300094 0247_ $$2ISSN$$a0893-3952
000300094 0247_ $$2ISSN$$a1530-0285
000300094 037__ $$aDKFZ-2025-00594
000300094 041__ $$aEnglish
000300094 082__ $$a610
000300094 1001_ $$aHelderman, Noah C$$b0
000300094 245__ $$aLower degree of microsatellite instability in colorectal carcinomas from MSH6-associated Lynch syndrome patients.
000300094 260__ $$aLondon$$bNature Publishing Group$$c2025
000300094 3367_ $$2DRIVER$$aarticle
000300094 3367_ $$2DataCite$$aOutput Types/Journal article
000300094 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1744363682_26757
000300094 3367_ $$2BibTeX$$aARTICLE
000300094 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300094 3367_ $$00$$2EndNote$$aJournal Article
000300094 500__ $$a#LA:D470# / Volume 38, Issue 7, July 2025, 100757
000300094 520__ $$aNumerous observational and molecular studies focusing on Lynch syndrome (LS) have revealed significant variation in the phenotype and molecular characteristics among carriers of pathogenic variants in mismatch repair genes (path_MMR). Recently, we demonstrated that colorectal carcinomas in path_MSH6 carriers exhibit fewer insertion/deletion mutations compared to CRCs from other MMR groups, raising the question of whether MSH6-mutated CRCs might display a relatively lower degree of microsatellite instability (MSI). Mutations at twenty coding microsatellites (cMS) were analyzed in 39 MSH6-, 18 MLH1-, 16 MSH2- and 22 PMS2-mutated CRCs and 35 sporadic MSI CRCs, and mutation frequencies and mutant allele ratios were compared among the different MMR-deficient groups. Considering factors such as HLA-A*02:01 type, B2M status, and the anticipated immunogenicity of frameshift peptides derived from cMS mutations, the identified cMS mutation profiles of MSH6-mutated CRCs were further investigated to assess their potential impact on immunotherapeutic strategies. MSH6-mutated CRCs exhibited lower mutation frequencies and mutant allele ratios across most cMS. Variation in cMS mutation patterns was observed both between different tumor regions and between tumor tissue and adjacent adenomatous tissue. The cMS mutations in MSH6-mutated CRCs demonstrated inverse correlations with the predicted immunogenicity of the resulting frameshift peptides, which may suggest negative selection of cell clones bearing highly immunogenic frameshift peptides. Overall, MSH6-mutated CRCs display a relatively lower degree of MSI and represent a biologically distinct subgroup of LS-associated CRCs. This lower MSI level may implicate an altered immune response compared to other MSI CRCs, which could have theoretical implications for the success of immunotherapy in MSH6-mutated CRCs. Future studies should carefully evaluate this possibility. If confirmed, these results would reinforce the notion of classifying LS as distinct syndromes associated with specific MMR genes.
000300094 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000300094 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000300094 650_7 $$2Other$$aLynch syndrome
000300094 650_7 $$2Other$$acoding microsatellites
000300094 650_7 $$2Other$$acolorectal cancer
000300094 650_7 $$2Other$$aframeshift peptides
000300094 650_7 $$2Other$$amicrosatellite instability
000300094 650_7 $$2Other$$amismatch repair
000300094 7001_ $$0P:(DE-He78)69cc7b8e3802bc74ab5f5738f177122d$$aStrobel, Fabian$$b1$$udkfz
000300094 7001_ $$0P:(DE-He78)a7f54298fcba548e34453b02202e6519$$aBohaumilitzky, Lena$$b2
000300094 7001_ $$aTerlouw, Diantha$$b3
000300094 7001_ $$avan der Werf-'t Lam, Anne-Sophie$$b4
000300094 7001_ $$avan Wezel, Tom$$b5
000300094 7001_ $$aMorreau, Hans$$b6
000300094 7001_ $$0P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f$$avon Knebel Doeberitz, Magnus$$b7
000300094 7001_ $$aNielsen, Maartje$$b8
000300094 7001_ $$0P:(DE-He78)3121b75683af3772ca9289d447889ed9$$aKloor, Matthias$$b9
000300094 7001_ $$0P:(DE-He78)07eef6d38a91f4642c810745c5bf5000$$aAhadova, Aysel$$b10$$eLast author$$udkfz
000300094 773__ $$0PERI:(DE-600)2041318-X$$a10.1016/j.modpat.2025.100757$$gp. 100757 -$$n7$$p100757$$tModern pathology$$v38$$x0893-3952$$y2025
000300094 909CO $$ooai:inrepo02.dkfz.de:300094$$pVDB
000300094 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69cc7b8e3802bc74ab5f5738f177122d$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000300094 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7f54298fcba548e34453b02202e6519$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000300094 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000300094 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3121b75683af3772ca9289d447889ed9$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000300094 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)07eef6d38a91f4642c810745c5bf5000$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000300094 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000300094 9141_ $$y2025
000300094 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-16$$wger
000300094 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000300094 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000300094 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000300094 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-16
000300094 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000300094 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-16
000300094 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-16
000300094 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-16
000300094 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000300094 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000300094 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMODERN PATHOL : 2022$$d2024-12-16
000300094 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMODERN PATHOL : 2022$$d2024-12-16
000300094 9202_ $$0I:(DE-He78)D470-20160331$$kD470$$lKKE Angewandte Tumorbiologie$$x0
000300094 9201_ $$0I:(DE-He78)D470-20160331$$kD470$$lKKE Angewandte Tumorbiologie$$x0
000300094 980__ $$ajournal
000300094 980__ $$aVDB
000300094 980__ $$aI:(DE-He78)D470-20160331
000300094 980__ $$aUNRESTRICTED